North America holds a notable share of the human rabies immunoglobulin market, driven by high awareness regarding rabies prevention, robust healthcare spending, and established treatment guidelines for post-exposure prophylaxis. The region benefits from strong pharmaceutical manufacturing capabilities, advanced healthcare facilities, and ongoing public health initiatives focused on infectious...